Diversity-focused British VC firm closes inaugural fund with high-profile backers


© Reuters. Diversity-focused British VC firm closes inaugural fund with high-profile backers

By Anna Irrera

(Reuters) – A new London-based venture capital aimed at funding tech companies whose founders come from traditionally under-represented groups said on Tuesday it closed its inaugural fund with backing from investors including TransferWise co-founder Taavet Hinrikus and later stage investment firm Atomico.

Ada Ventures, whose name is inspired by computer science pioneer Ada Lovelace, plans to invest the $34 million (£26.50 million) fund in UK technology companies aimed at underserved customer segments or whose founders are traditionally overlooked by VCs because of gender, race or background, it said.

Other fund backers include the British Business Bank, which will make the cornerstone investment, U.S.-based BlueSky Capital, Dubai-based Rasmala and Silicon Valley law firm Wilson Sonsini, the company said.

This year $92 of every $100 invested in tech companies in Europe went to founding teams that were all men, according to a study by Atomico. Around 84% of founders who raised external funding were white and 82% were university educated, the research also found.

Ada Ventures hopes to help change this by providing early stage equity to more diverse teams, founding partner Francesca Warner said in an interview.

“We felt like there needed to be a fund properly breaking down barriers for people who felt they couldn’t identify with the current venture capital options,” Warner said.

The firm will also invest in technology companies developing products and services aimed at overlooked segments, including ageing populations, women and people under 20, it said.

READ  Apple’s Trump bump

It will make initial investments of around 500,000 pounds ($641,500) and reserve around half of the fund for follow-on investments, it said.

It has already backed seven companies including Polipop, a company developing a flushable sanitary pads, and Juno Bio, a biotech company focused on decoding the vaginal microbiome to increase the success of IVF.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here